Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Realworld Cohort Study to Validate Effectiveness of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule Multicentric, Multinational, Prospective, Observational Study.

NCT05817110 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05817110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05817110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Realworld Cohort Study to Validate Effectiveness of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule Multicentric, Multinational, Prospective, Observational Study.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
April 20, 2023
Completion date
December 6, 2026
Enrollment
712 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lung malignancy